Thanks, I really appreciate your detailed posting here. It is helpful. When I was taking higher doses of Resveratrol with my regimen I got that "kite" feeling too. Interesting at times, but to me it was indicative of excessive dosing and prompts me to cut dose. In your case, however, high dosing is exactly what may be needed, and hopefully, for a short period. When do you plan on cutting doses? How are your recent test results doing? Is there remission yet? PSA levels?
My recent PSA was up by 27%. That's where it was 6 months ago. I attribute this to my following Bill Sard1's suggestion to take <<<OMG, the megadosing!!!>>> 8 capsules of L0ngev1nex a day, which he supplied. It's too early for another PSA with high dosing (3+ grams of RESV in the form of Nitro). I just recently cut out the Quercetin (in the form of 3 grams of MCT Quercetin plus 9 grams of Jarrow Quercetin) with the 3 grams of Nitro.
For safety sake and based on the research report on Resveratrol acting as a pro-oxidant in the morning and an anti-oxidant in the evening, I'm taking my other supplements like Pom capsules, Life Extension Mix, Blueberry Extract and the like in the evening. I take Resveratrol bucally only before noon because of the impact Resveratrol has on the circadian genes. The 100 mg. sublingual pure Testosterone I take twice a day (I take loads of DIM and other things to prevent E2 and DHT creation) appears to be working especially well the more I increase the amount of Resveratrol.
When will I go to a lower dose of Resveratrol? I'm going to take a run of 2-3 months like this, expect my PSA to plummet, then take a breather and cut back to say 1 gram of Nitro or micronized in whey protein isolate.
What Does This New England Journal of Medicine Paper Mean for Users of Finesteride 1 mg (Propecia®)?
The Prostate Cancer Prevention Trial reported in the July 17, 2003, issue of The New England Journal of Medicine studied the effect of finasteride 5 mg (Proscar®) on the development of prostate cancer:
over a 7-year period, in a randomized, placebo-controlled trial ending in February, 2003, in 18,882 men aged 55 or older, with normal prostates and PSA values were given finasteride to determine if a drug prescribed to millions of men to treat prostate gland enlargement can prevent or delay the appearance of prostate cancer in a population most susceptible to development of prostate cancer.
Headline results of the study:
Overall prevalence of prostate cancer in finasteride-treated men was reduced by 24.8% from the prevalence normally expected in men of this age and medical condition, indicating that finasteride 5mg (Proscar®) is effective in preventing or delaying the appearance of prostate cancer.
In men who developed prostate cancer during the study, finasteride 5 mg was associated with a small increased risk for developing a high-malignancy cancer. The reason for this small increased risk is not understood.
Meaning of the study for users of finasteride 1 mg (Propecia®):
Results of the study cannot be generalized from finasteride 5 g (Proscar®) used to treat prostate enlargement to the lower-dose finasteride 1 mg (Propecia®) used to treat hair loss due to androgenetic alopecia. Safety tests of Propecia® have been accepted by the Food and Drug Administration as an indication of safety for use in treating hair loss.
Introduction and Background
On July 17, 2003, the prestigious New England Journal of Medicine published “The Influence of Finasteride on the Development of Prostate Cancer”, a paper reporting the results of a seven-year, multi-center clinical trial. The purpose of the trial was to test the hypothesis that Proscar®, a 5 milligram formulation of finasteride used to treat enlargement of the prostate gland, might reduce risk for prostate cancer—a major cancer risk for men, especially for men of older age.
The “good news and bad news” findings of the study were widely reported in the media, and frequently misreported or misinterpreted. While the study was conducted with the 5 milligram formulation of finasteride (Proscar®), and was concerned only with prostate cancer prevention, the study results raised questions among patients as well as professionals regarding the use of finasteride 1 mg (Propecia®) for treatment of hair loss. The ISHRS believes that questions about the study results in relation to use of finasteride 1 mg (Propecia®) should be asked, but that questions as well as answers should be based upon (1) the facts as reported by the investigators, and (2) interpretation of the study results as reported by the investigators.
Why the Study Was Conducted
The androgenic (male) hormone testosterone and its more potent metabolite dihydrotestosterone are known to influence abnormal growth of tissue in the prostate gland. When abnormal growth is benign, the result is prostate enlargement (hypertrophy) and associated symptoms such as urinary retention. When the abnormal growth is malignant, the result is prostate cancer.
The drug finasteride inhibits the enzyme that converts testosterone into dihydrotestosterone . This reduces the amount of dihydrotestosterone in the body and the amount available to act on prostate tissue. In a 5 milligram formulation, finasteride (Proscar®) is prescribed to treat benign prostate enlargement.
The investigators designed the study to find out - would finasteride 5 mg (Proscar®), shown to be effective in treating benign prostate enlargement, also be effective in preventing or delaying the appearance of malignant growth of prostate tissue (prostate cancer)?
Androgenic hormones have many effects on many different tissues and organs, among them the hair follicle. Dihydrotestosterone has a potent role in causing hair loss due to androgenetic alopecia (See About hair loss for more information). Finasteride in a 1 milligram formulation (Propecia®) is prescribed as a treatment for hair loss. See Nonsurgical hair loss treatment options for more information.
Proscar® and Propecia®: Same Drug, Different Uses
It is important to note that only the effect of finasteride 5 mg (Proscar®) was studied. Proscar® is widely prescribed for its approved use in treating benign prostate enlargement. Lower-dose finasteride 1 mg (Propecia®), widely prescribed to treat hair loss due to androgenetic alopecia, was not used and was not discussed by the investigators. Some newspaper, TV and Web stories have not made the distinction, contributing to confusion about the study results.
The Study Protocol: Who Was Studied for How Long
The Prostate Cancer Prevention Trial was a prospective, randomized, placebo-controlled study—the “gold standard” for obtaining objective results. The study was carried out at 10 medical centers over a seven-year period ending in February, 2003.
Randomized into the study were 18,882 men, age 55 or older, who had normal prostates on physical examination and prostate-specific antigen (PSA) levels of 3.0 ng/ml or lower, indicating no benign or malignant enlargement. Half of the men received finasteride 5 mg (Proscar®) every day, and half received non-active placebo every day over the seven years of the study. Medical and laboratory examinations were performed at regular intervals, and prostate biopsy performed as indicated by results of these examinations. All men were also offered a prostate biopsy at the end of the study. The investigators assumed that 60% of the men either would have an interim diagnosis of prostate cancer during the study, or would have an end-of-study biopsy to detect or rule out the presence of cancer.
Results of the Study
The study was ended in February, 2003, 15 months early, when investigators found that all study objectives had been met.
http://www.ishrs.org...tate-cancer.htm